Gracell Bio (GRCL) Stock Forecast, Price Target & Predictions
GRCL Stock Forecast
Gracell Bio stock forecast is as follows: an average price target of $6.00 (represents a -41.46% downside from GRCL’s last price of $10.25) and a rating consensus of 'Buy', based on 3 wall street analysts offering a 1-year stock forecast.
GRCL Price Target
The average price target for Gracell Bio (GRCL) is $6.00 based on 1-year price targets from 3 Wall Street analysts in the past 3 months, with a price target range of $6.00 to $6.00. This represents a potential -41.46% downside from GRCL's last price of $10.25.
GRCL Analyst Ratings
According to 3 Wall Street analysts, Gracell Bio's rating consensus is 'Buy'. The analyst rating breakdown for GRCL stock is 0 'Strong Buy' (0.00%), 2 'Buy' (66.67%), 0 'Hold' (0.00%), 1 'Sell' (33.33%), and 0 'Strong Sell' (0.00%).
Gracell Bio Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Dec 08, 2022 | - | H.C. Wainwright | $6.00 | $2.63 | 128.14% | -41.46% |
The latest Gracell Bio stock forecast, released on Dec 08, 2022 by H.C. Wainwright company, set a price target of $6.00, which represents a 128.14% increase from the stock price at the time of the forecast ($2.63), and a -41.46% decrease from GRCL last price ($10.25).
Gracell Bio Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | - |
| Avg Price Target | - | - | - |
| Last Closing Price | $10.25 | $10.25 | $10.25 |
| Upside/Downside | -100.00% | -100.00% | -100.00% |
In the current month, the average price target of Gracell Bio stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Gracell Bio's last price of $10.25. This month's average price target is down NaN% compared to last quarter, and down NaN% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Sep 22, 2022 | Citigroup | - | Negative | Initialise |
| Jun 01, 2022 | Cantor Fitzgerald | - | Overweight | Initialise |
| Apr 04, 2022 | BTIG | - | Buy | Initialise |
Gracell Bio's last stock rating was published by Citigroup on Sep 22, 2022. The company Initialise its GRCL rating from "null" to "Negative".
Gracell Bio Financial Forecast
Gracell Bio Revenue Forecast
| Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 21 | Sep 21 | |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | $366.00K |
| Avg Forecast | - | - | - | - | - | - | $125.00K | $366.00K | $366.00K |
| High Forecast | - | - | - | - | - | - | $88.83K | $260.09K | $439.20K |
| Low Forecast | - | - | - | - | - | - | $146.28K | $428.30K | $292.80K |
| # Analysts | 10 | 10 | 10 | 10 | 10 | 18 | 10 | 10 | 20 |
| Surprise % | - | - | - | - | - | - | - | - | 1.00% |
Gracell Bio's average Quarter revenue forecast for Dec 21 based on 10 analysts is $366.00K, with a low forecast of $428.30K, and a high forecast of $260.09K. GRCL's average Quarter revenue forecast represents a 0.00% decrease compared to the company's last Quarter revenue of $366.00K (Sep 21).
Gracell Bio EBITDA Forecast
| Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 21 | Sep 21 | |
|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 10 | 10 | 10 | 10 | 10 | 18 | 10 | 10 | 20 |
| EBITDA | - | - | - | - | - | - | $-151.34M | $-127.26M | $-128.20M |
| Avg Forecast | - | - | - | - | - | - | $75.00K | $219.60K | $-128.20M |
| High Forecast | - | - | - | - | - | - | $53.30K | $156.06K | $-102.56M |
| Low Forecast | - | - | - | - | - | - | $87.77K | $256.98K | $-153.84M |
| Surprise % | - | - | - | - | - | - | -2017.83% | -579.50% | 1.00% |
undefined analysts predict GRCL's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Gracell Bio's previous annual EBITDA (undefined) of $NaN.
Gracell Bio Net Income Forecast
| Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 21 | Sep 21 | |
|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 10 | 10 | 10 | 10 | 10 | 18 | 10 | 10 | 20 |
| Net Income | - | - | - | - | - | - | $-151.73M | $-116.26M | $-129.28M |
| Avg Forecast | $105.23M | $91.66M | $107.62M | $-18.43M | $-19.12M | $-25.26M | $-23.89M | $8.19M | $-129.28M |
| High Forecast | $67.17M | $58.51M | $68.70M | $-17.07M | $-13.65M | $-16.12M | $-15.25M | $5.23M | $-103.43M |
| Low Forecast | $127.62M | $111.16M | $130.52M | $-20.48M | $-20.48M | $-30.63M | $-28.98M | $9.94M | $-155.14M |
| Surprise % | - | - | - | - | - | - | 6.35% | -14.19% | 1.00% |
Gracell Bio's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. GRCL's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Gracell Bio SG&A Forecast
| Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 21 | Sep 21 | |
|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 10 | 10 | 10 | 10 | 10 | 18 | 10 | 10 | 20 |
| SG&A | - | - | - | - | - | - | $29.09M | $32.00M | $42.86M |
| Avg Forecast | - | - | - | - | - | - | - | - | $42.86M |
| High Forecast | - | - | - | - | - | - | - | - | $51.43M |
| Low Forecast | - | - | - | - | - | - | - | - | $34.29M |
| Surprise % | - | - | - | - | - | - | - | - | 1.00% |
Gracell Bio's average Quarter SG&A projection for Jun 23 is -, based on 18 Wall Street analysts, with a range of - to -. The forecast indicates a -100.00% fall compared to GRCL last annual SG&A of $29.09M (Mar 23).
Gracell Bio EPS Forecast
| Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 21 | Sep 21 | |
|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 10 | 10 | 10 | 10 | 10 | 18 | 10 | 10 | 20 |
| EPS | - | - | - | - | - | - | $-2.24 | $-1.77 | $-1.90 |
| Avg Forecast | $1.54 | $1.34 | $1.58 | $-0.27 | $-0.28 | $-0.37 | $-0.35 | $0.12 | $-0.05 |
| High Forecast | $0.98 | $0.86 | $1.01 | $-0.25 | $-0.20 | $-0.24 | $-0.22 | $0.08 | $-0.03 |
| Low Forecast | $1.87 | $1.63 | $1.91 | $-0.30 | $-0.30 | $-0.45 | $-0.42 | $0.15 | $-0.06 |
| Surprise % | - | - | - | - | - | - | 6.40% | -14.75% | 38.00% |
According to undefined Wall Street analysts, Gracell Bio's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to GRCL previous annual EPS of $NaN (undefined).
Gracell Bio Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| SPRO | Spero Therapeutics | $1.37 | $10.00 | 629.93% | Buy |
| CHRS | Coherus BioSciences | $1.30 | $9.00 | 592.31% | Hold |
| XFOR | X4 Pharmaceuticals | $0.71 | $3.67 | 416.90% | Buy |
| CTMX | CytomX Therapeutics | $1.23 | $5.77 | 369.11% | Buy |
| DAWN | Day One Biopharmaceuticals | $14.13 | $38.80 | 174.59% | Buy |
| ABOS | Acumen Pharmaceuticals | $2.60 | $7.00 | 169.23% | Buy |
| INZY | Inozyme Pharma | $6.00 | $14.67 | 144.50% | Buy |
| ERAS | Erasca | $2.97 | $7.00 | 135.69% | Buy |
| NXTC | NextCure | $1.40 | $3.00 | 114.29% | Buy |
| DSGN | Design Therapeutics | $5.54 | $9.67 | 74.55% | Buy |
| BOLT | Bolt Biotherapeutics | $0.61 | $1.00 | 63.93% | Hold |
| TERN | Terns Pharmaceuticals | $8.96 | $12.50 | 39.51% | Buy |
| AMLX | Amylyx Pharmaceuticals | $2.62 | $3.33 | 27.10% | Buy |
| BPMC | Blueprint Medicines | $88.90 | $101.50 | 14.17% | Buy |
| GRCL | Gracell Bio | $10.25 | $6.00 | -41.46% | Buy |
GRCL Forecast FAQ
Is Gracell Bio a good buy?
Yes, according to 3 Wall Street analysts, Gracell Bio (GRCL) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 2 'Buy' recommendations, accounting for 66.67% of GRCL's total ratings.
What is GRCL's price target?
Gracell Bio (GRCL) average price target is $6 with a range of $6 to $6, implying a -41.46% from its last price of $10.25. The data is based on 3 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Gracell Bio stock go up soon?
According to Wall Street analysts' prediction for GRCL stock, the company can go down by -41.46% (from the last price of $10.25 to the average price target of $6), down by -41.46% based on the highest stock price target, and down by -41.46% based on the lowest stock price target.
Can Gracell Bio stock reach $20?
GRCL's average twelve months analyst stock price target of $6 does not support the claim that Gracell Bio can reach $20 in the near future.
What are Gracell Bio's analysts' financial forecasts?
GRCL's analysts financial forecasts for the fiscal year (Dec 2023) are as follows: average revenue is $125K (high $88.83K, low $146.28K), average EBITDA is $75K (high $53.3K, low $87.76K), average net income is $-86.703M (high $-62.097M, low $-101M), average SG&A $0 (high $0, low $0), and average EPS is $-1.27 (high $-0.91, low $-1.473).
Did the GRCL's actual financial results beat the analysts' financial forecasts?
Based on Gracell Bio's last annual report (Dec 2021), the company's revenue was $366K, which missed the average analysts forecast of $732K by -50.00%. Apple's EBITDA was $-385M, beating the average prediction of $-128M by 200.94%. The company's net income was $-453M, beating the average estimation of $-121M by 274.14%. Apple's SG&A was $137.04M, beating the average forecast of $42.86M by 219.73%. Lastly, the company's EPS was $-6.89, missing the average prediction of $0.07 by -9942.86%. In terms of the last quarterly report (Sep 2021), Gracell Bio's revenue was $366K, beating the average analysts' forecast of $366K by 0%. The company's EBITDA was $-128M, beating the average prediction of $-128M by 0%. Gracell Bio's net income was $-129M, beating the average estimation of $-129M by 0%. The company's SG&A was $42.86M, beating the average forecast of $42.86M by 0%. Lastly, the company's EPS was $-1.9, beating the average prediction of $-0.05 by 3700.00%